SUMMIT THERAPEUTICS INC COM - Stock (SMMT) Institutional Ownership

CUSIP: 86627R102

13F Institutional Holders and Ownership History from Q1 2015 to Q3 2025

Type / Class
Equity / Stock
Symbol
SMMT on Nasdaq
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 86627R102?
CUSIP 86627R102 identifies SMMT - SUMMIT THERAPEUTICS INC COM - Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Institutional Holders of SUMMIT THERAPEUTICS INC COM - Stock (SMMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 0 $0 -$81,523 0
2025 Q2 3,831 $81,523 +$50,630 $21.28 12
2025 Q1 2,320 $44,431 -$161,205 $19.29 10
2024 Q4 11,418 $203,755 +$187,963 $17.84 7
2024 Q3 885 $19,382 +$417 $21.90 2
2024 Q2 866 $6,755 +$2,558 $7.80 2
2024 Q1 548 $2,268 -$28,509 $4.12 2
2023 Q4 11,483 $29,970 -$665 $2.61 2
2023 Q3 11,738 $21,950 -$90,672 $1.87 2
2023 Q2 47,852 $120,108 -$8,710 $2.51 4
2023 Q1 51,994 $90,990 +$81,319 $1.75 6
2022 Q4 5,526 $23,486 -$10,764 $4.25 4
2022 Q3 16,245 $19,000 +$2,436 $1.16 3
2022 Q2 14,445 $14,000 +$192 $1.00 3
2022 Q1 14,245 $34,000 +$5,000 $2.49 3
2021 Q4 11,245 $30,000 -$3,000 $2.67 1
2021 Q3 11,930 $59,000 -$5,757 $4.74 3
2021 Q2 12,983 $96,000 +$9,263 $7.01 4
2021 Q1 11,674 $68,000 -$240,569 $5.70 3
2020 Q4 62,690 $295,000 -$30,000 $4.73 5
2020 Q3 68,600 $235,000 -$24,103,970 $3.42 3
2020 Q2 8,186,422 $24,313,970 -$659,803 $2.97 18
2020 Q1 8,401,772 $19,917,000 +$13,659,842 $2.37 10
2019 Q4 2,744,086 $4,390,000 +$131,030 $1.60 12
2019 Q3 2,657,572 $4,757,000 -$8,605 $1.79 11
2019 Q2 2,664,012 $3,371,000 +$56,118 $1.27 10
2019 Q1 2,594,256 $4,749,000 -$215,622 $1.83 12
2018 Q4 2,882,824 $3,315,000 -$169,873 $1.15 10
2018 Q3 2,944,738 $6,536,000 -$1,187,730 $2.22 12
2018 Q2 3,449,978 $8,452,000 -$8,099,737 $2.45 14
2018 Q1 4,143,303 $53,319,000 +$2,089,355 $12.90 19
2017 Q4 4,017,625 $44,513,000 -$755,148 $11.08 20
2017 Q3 4,054,940 $50,865,000 +$17,110,046 $12.55 20
2017 Q2 2,690,736 $30,479,000 -$62,231 $11.33 14
2017 Q1 2,694,940 $35,802,000 -$9,121 $13.28 15
2016 Q4 2,695,646 $23,072,000 -$269,382 $8.56 11
2016 Q3 2,727,116 $24,762,000 -$66,243 $9.06 12
2016 Q2 2,734,292 $21,923,000 -$365,239 $7.91 10
2016 Q1 2,669,891 $18,277,000 -$323,116 $6.82 8
2015 Q4 2,835,071 $32,595,000 -$36,516 $11.50 10
2015 Q3 2,838,493 $29,548,000 +$538,260 $10.41 10
2015 Q2 2,786,113 $29,637,000 +$879,531 $10.56 10
2015 Q1 2,680,373 $33,209,000 +$33,209,000 $12.39 7